trending Market Intelligence /marketintelligence/en/news-insights/trending/8yyHRIUGFU1nvedVDDgaQA2 content esgSubNav
In This List

Galmed Pharmaceuticals launches $35M offering of ordinary shares

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Galmed Pharmaceuticals launches $35M offering of ordinary shares

Galmed Pharmaceuticals Ltd. plans to sell up to $35.0 million of its ordinary shares in an at-the-market equity offering from time to time.

Stifel Nicolaus & Co. Inc. is acting as the sales agent for the offering.